Achillion Pharmaceuticals, Inc.
| Nasdaq: ACHN
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative treatments for infectious diseases. The company is currently engaged in the development of antivirals for the treatment of chronic hepatitis C infection and resistant bacterial infections. Its products include Sovaprevir (ACH-1625), ACH-2684, ACH-2928, ACH-3102, ACH-702 and Elvucitabine. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.